相关实验视频
Updated: Jun 19, 2025

04:49
Technique for Intranasal Administration of α-Synuclein Aggregates
Published on: November 8, 2024
428
病运动和神经精神症状集群药物治疗:结构化范围审查
Roseanagh Hogg1, John Centola2, Eugene Ace McDermott3
1Oxford University Hospitals NHS Foundation Trust Palliative Care, Oxford, Oxfordshire, UK rosie.hogg@ouh.nhs.uk.
BMJ supportive & palliative care
|July 26, 2024
概括
药理疗法在控制病的运动和神经精神症状方面表现出一定效果. 然而,缺乏高质量的证据,需要进一步进行标准化研究,以改善患者护理.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 神经学 神经学
背景情况:
- 病是一种罕见的,致命的神经退行性疾病,具有具有挑战性的症状.
- 有效的症状管理对于患者的生活质量至关重要.
研究的目的:
- 审查关于药理管理病症状的证据.
- 在建议中纳入专家和相对经验.
主要方法:
- 使用COVIDENCE系统审查工具进行了范围审查.
- 在四个数据库中搜索,发现了120篇论文.
- 由于数据有限,进行了数据提取和主题综合.
主要成果:
- 类药物,抗精神病药物和抗药物显示出对运动和神经精神病症状的新兴疗效.
- 国际专家意见证实了这些发现和相关的挑战.
结论:
- 对于病症状管理的高质量证据的显著缺乏仍然存在.
- 需要标准化的纵向研究来建立一个强大的证据基础.
- 改善的证据将指导更好的症状控制和终身护理.
相关概念视频
Alzheimer's Disease: Treatment
172
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
172
Parkinson's Disease: Treatment
241
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
241
Parkinson's Disease: Overview
510
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
510
Psychosis: Goals of Pharmacotherapy
114
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
114
Psychosis and Antipsychotic Drugs: Overview
214
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
214
Drug Therapy
41
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
41

